Literature DB >> 16034010

Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery.

Geoffrey J Service1, Geoffrey B Thompson, F John Service, James C Andrews, Maria L Collazo-Clavell, Ricardo V Lloyd.   

Abstract

We describe six patients (five women and one man; median age, 47 years; range, 39 to 54) with postprandial symptoms of neuroglycopenia owing to endogenous hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass surgery. Except for equivocal evidence in one patient, there was no radiologic evidence of insulinoma. Selective arterial calcium-stimulation tests, positive in each patient, were used to guide partial pancreatectomy. Nesidioblastosis was identified in resected specimens from each patient, and multiple insulinomas were identified in one. Hypoglycemic symptoms diminished postoperatively. We speculate that hyperfunction of pancreatic islets did not lead to obesity but that beta-cell trophic factors may have increased as a result of gastric bypass.

Entities:  

Mesh:

Year:  2005        PMID: 16034010     DOI: 10.1056/NEJMoa043690

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  219 in total

1.  Acarbose improves hypoglycaemia following gastric bypass surgery without increasing glucagon-like peptide 1 levels.

Authors:  Juan Patricio Valderas; Jessica Ahuad; Lorena Rubio; Manuel Escalona; Felipe Pollak; Alberto Maiz
Journal:  Obes Surg       Date:  2012-04       Impact factor: 4.129

2.  Population-based study of severe hypoglycemia requiring emergency medical service assistance reveals unique findings.

Authors:  Ajay K Parsaik; Rickey E Carter; Vishwanath Pattan; Lucas A Myers; Hamit Kumar; Steven A Smith; Christopher S Russi; James A Levine; Ananda Basu; Yogish C Kudva
Journal:  J Diabetes Sci Technol       Date:  2012-01-01

Review 3.  Type 2 diabetes mellitus: a possible surgically reversible intestinal dysfunction.

Authors:  Priscila C Sala; Raquel S Torrinhas; Steven B Heymsfield; Dan L Waitzberg
Journal:  Obes Surg       Date:  2012-01       Impact factor: 4.129

Review 4.  Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass.

Authors:  C Dirksen; N B Jørgensen; K N Bojsen-Møller; S H Jacobsen; D L Hansen; D Worm; J J Holst; S Madsbad
Journal:  Diabetologia       Date:  2012-04-27       Impact factor: 10.122

5.  Laparoscopic reconversion of Roux-en-Y gastric bypass to original anatomy: technique and preliminary outcomes.

Authors:  Giovanni Dapri; Guy Bernard Cadière; Jacques Himpens
Journal:  Obes Surg       Date:  2011-08       Impact factor: 4.129

6.  Insulin secretion and insulin-producing tumors.

Authors:  Jean-Marc Guettier; Phillip Gorden
Journal:  Expert Rev Endocrinol Metab       Date:  2010-03-01

7.  A survey of dumping symptomatology after gastric bypass with or without lesser omental transection.

Authors:  Constantine T Frantzides; Mark A Carlson; Valerie K Shostrom; Jacob Roberts; George Stavropoulos; George Ayiomamitis; Alexander Frantzides
Journal:  Obes Surg       Date:  2011-02       Impact factor: 4.129

8.  Heterogeneity of proliferative markers in pancreatic β-cells of patients with severe hypoglycemia following Roux-en-Y gastric bypass.

Authors:  Mary-Elizabeth Patti; Allison B Goldfine; Jiang Hu; Dag Hoem; Anders Molven; Jeffrey Goldsmith; Wayne H Schwesinger; Stefano La Rosa; Franco Folli; Rohit N Kulkarni
Journal:  Acta Diabetol       Date:  2017-05-17       Impact factor: 4.280

9.  Resolution of diabetes mellitus and metabolic syndrome following Roux-en-Y gastric bypass and a variant of biliopancreatic diversion in patients with morbid obesity.

Authors:  Theodore K Alexandrides; George Skroubis; Fotis Kalfarentzos
Journal:  Obes Surg       Date:  2007-02       Impact factor: 4.129

10.  Short-, mid- and long-term results of Larrad biliopancreatic diversion.

Authors:  Alvaro Larrad-Jiménez; Carlos Sánchez-Cabezudo Díaz-Guerra; Pedro de Cuadros Borrajo; Irene Bretón Lesmes; Basilio Moreno Esteban
Journal:  Obes Surg       Date:  2007-02       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.